HC Wainwright Has Lowered Expectations for Cytosorbents (NASDAQ:CTSO) Stock Price

Cytosorbents (NASDAQ:CTSO) had its price target reduced by analysts at HC Wainwright from $1.00 to $0.75 in a note issued to investors on Friday,Benzinga reports. The firm currently has a “neutral” rating on the medical research company’s stock. HC Wainwright’s price objective suggests a potential upside of 13.64% from the stock’s previous close.

Other equities research analysts have also issued research reports about the company. Weiss Ratings restated a “sell (e+)” rating on shares of Cytosorbents in a research report on Tuesday, October 14th. D. Boral Capital restated a “buy” rating and set a $10.00 price target on shares of Cytosorbents in a report on Tuesday, September 16th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Cytosorbents has an average rating of “Hold” and an average price target of $5.38.

Cytosorbents Trading Down 0.8%

CTSO opened at $0.66 on Friday. Cytosorbents has a twelve month low of $0.60 and a twelve month high of $1.61. The company has a fifty day moving average of $0.87 and a 200-day moving average of $0.95. The stock has a market cap of $41.42 million, a PE ratio of -3.88 and a beta of 1.28. The company has a quick ratio of 1.96, a current ratio of 2.34 and a debt-to-equity ratio of 1.24.

Cytosorbents (NASDAQ:CTSO) last issued its quarterly earnings results on Friday, January 3rd. The medical research company reported ($0.08) EPS for the quarter. Cytosorbents had a negative net margin of 25.58% and a negative return on equity of 111.97%. The firm had revenue of $8.61 million for the quarter. On average, sell-side analysts predict that Cytosorbents will post -0.3 EPS for the current year.

Hedge Funds Weigh In On Cytosorbents

A number of institutional investors have recently modified their holdings of CTSO. Avenir Corp raised its holdings in shares of Cytosorbents by 0.3% in the second quarter. Avenir Corp now owns 5,058,537 shares of the medical research company’s stock valued at $6,475,000 after purchasing an additional 13,619 shares during the last quarter. Vanguard Group Inc. grew its position in Cytosorbents by 3.7% in the 3rd quarter. Vanguard Group Inc. now owns 2,204,294 shares of the medical research company’s stock worth $2,059,000 after purchasing an additional 79,535 shares in the last quarter. CM Management LLC increased its stake in Cytosorbents by 3.1% in the 3rd quarter. CM Management LLC now owns 1,288,128 shares of the medical research company’s stock valued at $1,203,000 after buying an additional 38,128 shares during the last quarter. GSA Capital Partners LLP bought a new position in shares of Cytosorbents during the 3rd quarter worth approximately $105,000. Finally, Goldman Sachs Group Inc. boosted its stake in shares of Cytosorbents by 149.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 62,662 shares of the medical research company’s stock worth $63,000 after buying an additional 37,519 shares during the last quarter. 32.87% of the stock is owned by institutional investors and hedge funds.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.